---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-22-000083"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:20:28.104212+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q1 revenue up 18% to $26.9M; net loss widens to $24.6M; raises 2022 guidance

## Summary
- Revenue $26.9M (+18% YoY); adjusted revenue $26.3M (+50% YoY); net loss ($24.6M) vs ($4.3M) prior year.
- Total test reports 8,627 (+68% YoY); DecisionDx-Melanoma +48%, DecisionDx-SCC +117%.
- 2022 total revenue guidance raised to $118-123M from $115-120M.
- Acquired AltheaDx/IDgenetix PGx test for mental health in April 2022; adds ~$5B TAM.
- Operating cash flow ($21.4M) vs ($3.6M); adjusted EBITDA ($11.4M) vs $0.9M.

## SEC filing metadata
- accession: 0001447362-22-000083
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000083/0001447362-22-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000083/cstl-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-22-000083
- JSON: https://secwatch.observer/filing/0001447362-22-000083.json
- Plain text: https://secwatch.observer/filing/0001447362-22-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.